J3358 HCPCS code: Ustekinumab, for intravenous injection, 1 mg
J3358 is the HCPCS Level II code for ustekinumab, for intravenous injection, 1 mg. In 2024 Medicare paid an average of $9.57 per service for J3358 across 446,416 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 520 per day on outpatient hospital claims. Medicare volume fell 23% from 2022 to 2024 (581,836 to 446,416 services). In 2024, about 836 clinicians billed Medicare for J3358 for 1,049 beneficiaries; Texas, Florida, California accounted for 33% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2018-01-01 |
| Last action effective | 2018-01-01 |
Who bills J3358 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 836 |
| Medicare beneficiaries | 1,049 |
| States with claims | 28 |
| Share of services in top 3 states (Texas, Florida, California) | 33% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3358, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 581,836 | 1,401 | $11.45 | $9.13 |
| 2023 | 540,523 | 1,291 | $11.82 | $9.41 |
| 2024 | 446,416 | 1,049 | $12.02 | $9.57 |
States with the most J3358 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 48,230 | $9.61 |
| Florida | 42,952 | $9.46 |
| California | 39,007 | $9.85 |
| Georgia | 23,140 | $9.57 |
| Pennsylvania | 21,320 | $9.93 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 520 | Prescribing Information |
| practitioner claims | 520 | Prescribing Information |
What changed for J3358
- 2018-01-01: J3358 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3358?
J3358 is the HCPCS Level II code for ustekinumab, for intravenous injection, 1 mg. Short descriptor: "Ustekinumab, iv inject, 1 mg".
How much does Medicare pay for J3358?
In 2024, the average Medicare payment was $9.57 per service (average allowed $12.02).
Does Medicare cover J3358?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J3358 can be billed per day?
520 on outpatient hospital claims; 520 on practitioner claims (NCCI medically unlikely edits).
Related J33 codes
- J3300 — Injection, triamcinolone acetonide (triesence), preservative free, 1 mg
- J3301 — Injection, triamcinolone acetonide, not otherwise specified, 10 mg
- J3302 — Injection, triamcinolone diacetate, per 5 mg
- J3303 — Injection, triamcinolone hexacetonide, per 5 mg
- J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- J3305 — Injection, trimetrexate glucuronate, per 25 mg
- J3310 — Injection, perphenazine, up to 5 mg
- J3315 — Injection, triptorelin pamoate, 3.75 mg
- J3316 — Injection, triptorelin, extended-release, 3.75 mg
- J3320 — Injection, spectinomycin dihydrochloride, up to 2 gm
- J3350 — Injection, urea, up to 40 gm
- J3355 — Injection, urofollitropin, 75 iu
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3358
- Watch J3358 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3358
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.